Algeta to arm Genzyme antibody with thorium-227 payload
This article was originally published in Scrip
Algeta has established a research collaboration with Genzyme to evaluate the potential of its thorium-227 platform, "the first of a series of deals this year" concerning the platform, the Norwegian company told Scrip.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.